As expected, TβRI inhibitors SX-007 and SD-208 can restore effector cell responses to tumour cells with greater release of cytotoxic granules and pro-inflammatory cytokines, delineating the negative regulation imposed by TGF-β on anti-tumour effector cell activity [174,179]. The gene discussed is TGFB1; the disease is neoplasm.